Rho is a presynaptic activator of neurotransmitter release at pre-existing synapses in C. elegans.
Rho is a presynaptic activator of neurotransmitter release at pre-existing synapses in *C. elegans*

Rachel McMullan, Emma Hiley, Paul Morrison, and Stephen J. Nurrish

MRC Cell Biology Unit, MRC Laboratory for Molecular Cell Biology and Department of Pharmacology, University College, London WC1E 6BT, United Kingdom

Rho GTPases have important roles in neuronal development, but their function in adult neurons is less well understood. We demonstrate that presynaptic changes in Rho activity at *Caenorhabditis elegans* neuromuscular junctions can radically change animal behavior via modulation of two separate pathways. In one, presynaptic Rho increases acetylcholine (ACh) release by stimulating the accumulation of diacylglycerol (DAG) and the DAG-binding protein UNC-13 at sites of neurotransmitter release; this pathway requires binding of Rho to the DAG kinase DGK-1. A second DGK-1-independent mechanism is revealed by the ability of a Rho inhibitor (C3 transferase) to decrease levels of release even in the absence of DGK-1; this pathway is independent of UNC-13 accumulation at release sites. We do not detect any Rho-induced changes in neuronal morphology or synapse number; thus, Rho facilitates synaptic transmission by a novel mechanism. Surprisingly, many commonly available human RhoA constructs contain an uncharacterized mutation that severely reduces binding of RhoA to DAG kinase. Thus, a role for RhoA in controlling DAG levels is likely to have been underestimated.

*Keywords*: RhoA; animal behavior; synaptic vesicle release; DAG kinase; Munc13; *C. elegans*

Supplemental material is available at http://www.genesdev.org.

Received July 18, 2005; revised version accepted October 31, 2005.
We report here that RHO-1 can enhance ACh release by at least two mechanisms—one dependent on the diacylglycerol (DAG) kinase DGK-1 and one DGK-1-independent. We also show that RHO-1 stimulates synaptic signaling by increasing muscle sensitivity to ACh. Thus, RHO-1 can use three distinct pathways to strengthen synaptic signaling at the \textit{C. elegans} neuromuscular junction.

**Results**

**RHO-1 regulates neurotransmitter release at neuromuscular junctions**

We used the \textit{Clostridium botulinum}-derived C3 transferase to inhibit the function of RHO-1 in \textit{C. elegans}. C3 transferase ADP-ribosylates and inactivates Rho without affecting other Rho family proteins, including Rac and Cdc42 (Aktories and Hall 1989). Expression of N-terminally GFP-tagged C3 transferase from an inducible heat-shock promoter in adult \textit{C. elegans} resulted in a major change in behavior, greatly decreasing animal movement as measured by a decrease in body bends per minute and very shallow body bends (Fig. 1A,B). To test whether RHO-1 acts pre- or post-synaptically, we expressed C3 transferase in ACh-releasing neurons, using the promoter for the \textit{unc-17} gene, which encodes the ACh transporter in synaptic vesicles (Alfonso et al. 1993). These animals also displayed decreased movement compared with wild-type animals (Fig. 1A,B), confirming that inhibition of endogenous RHO-1 signaling in ACh-releasing cells changes \textit{C. elegans} locomotion.

To further test the role of RHO-1 in neurotransmitter release, we expressed a constitutively active RHO-1(G14V) mutant from either an inducible heat-shock promoter or the \textit{unc-17} promoter. In both cases, expression of RHO-1(G14V) also changed adult behavior, but in this case movement was greatly increased, as measured

---

**Figure 1.** RHO-1 signaling alters animal behavior and acetylcholine release. Mutant behavioral assays and transgenic animals were as described in Materials and Methods. (A) Inhibition of endogenous RHO-1 by expression of C3 transferase from heat-shock [hs:] or neuronal [N:] [using the \textit{unc-17} promoter] promoters decreased locomotion, whereas expression of a constitutively active RHO-1(G14V) mutant from heat-shock or neuronal promoters increased locomotion. Statistical analysis was performed using a two-tailed t-test, and significance is indicated with two asterisks (**, p < 0.001). (B) Locomotion phenotypes of the mutants described in this study. Inhibition of endogenous RHO-1 by heat-shock [hs:C3T] or presynaptic [from the \textit{unc-17} promoter, N:C3T] expression of C3 transferase causes flattened sinusoidal tracks compared with wild type. Heat-shock [hs:RHO-1(G14V)] and presynaptic [N:RHO-1(G14V)] expression of RHO-1(G14V) results in exaggerated sinusoidal tracks compared with wild type. (C–E) Synaptic release of endogenous acetylcholine (ACh) was measured by determining the onset of paralysis induced by the acetylcholinesterase inhibitor aldicarb. Expression of C3 transferase from either heat-shock [hs:C3 transferase + hs] or the presynaptic \textit{unc-17} [N:C3T] [D] promoter delayed the onset of paralysis of animals treated with aldicarb relative to non-heat-shocked animals [hs:C3 transferase -- hs] or wild-type animals [wt], suggesting a decrease in levels of ACh release. In contrast, expression of the constitutively active RHO-1(G14V) from either heat-shock [RHO-1(G14V) + hs] or \textit{unc-17} [N:C3T] [D] promoters results in a faster onset of paralysis relative to non-heat-shocked animals [RHO-1(G14V) -- hs] or wild-type (wt) animals, suggesting that the normal role of RHO-1 activation is to increase ACh release. Error bars indicate standard error of the mean.
by an increase in body bends per minute, and animals produced exaggerated body bends with increased bend amplitude, producing loopy locomotion (Fig. 1A,B).

To relate the behavioral effects of changing RHO-1 activity to ACh levels, we quantified the responsiveness of animals to the acetylcholinesterase inhibitor aldicarb. Aldicarb prevents the removal of endogenously released ACh, which allows ACh to build up to a level sufficient to hypercontract the body wall muscles and cause paralysis in wild-type animals, but not in mutants that are defective in ACh release [Nonet et al. 1993, Nguyen et al. 1995, Miller et al. 1996]. In the presence of aldicarb, heat-shock-induced expression of C3 transferase in adult animals strongly reduced the extent of paralysis compared with both noninduced animals and wild-type animals [Fig. 1C]. Presynaptic expression of C3 transferase from the unc-17 promoter also increased resistance to aldicarb treatment compared with wild-type animals [Fig. 1D]. In contrast, heat-shock expression of the constitutively active RHO-1(G14V) mutant in adult animals resulted in hypersensitivity to aldicarb [Fig. 1E]. RHO-1(G14V) acted presynaptically, as animals expressing activated RHO-1(G14V) in motor neurons from the unc-17 promoter also became paralyzed faster with aldicarb treatment compared with wild-type animals [Fig. 1D]. Taken together, these results suggest that activation of RHO-1 enhances ACh release, leading to changes in behavior.

RHO-1 enhances ACh release at pre-existing synapses

In principle, RHO-1 could increase ACh release either by increasing ACh release at existing synapses, by stimulating the formation of new ACh-releasing synapses, or both. We tested the possibility that RHO-1 increased the formation of new synapses in two ways. First, we looked for changes in neuronal connectivity by assessing GFP-labeled motor neurons and found no obvious morphological differences in wild-type, C3 transferase, and RHO-1(G14V)-expressing motor neurons (Supplementary Fig. 2). Similarly, expression of RHO-1(G14V) in ACh-releasing neurons to measure the number of release sites before and after heat-shock-induced expression of the constitutively active RHO-1(G14V). After heat-shock induction of RHO-1(G14V), we saw no change in the number of SNB-1::CFP puncta compared with noninduced animals [3.2 ± 0.4 vs. 2.9 ± 0.2 puncta per 10 µm, mean ± SEM; Supplementary Fig. 2]. Similarly, expression of RHO-1(G14V) in ACh-releasing neurons from the unc-17 promoter did not alter the number of SNB-1::CFP puncta when compared with wild-type controls [3.2 ± 0.2 vs. 3.4 ± 0.1 puncta per 10 µm, mean ± SEM; Supplementary Fig. 2]. We conclude that RHO-1(G14V) exerts its effects by increasing ACh release at pre-existing synapses and not by increasing the number of synapses. C3 transferase was tagged with GFP, and we were unable to visualize SNB-1::CFP puncta, thus, it is possible that inhibition of endogenous RHO-1 may cause a decrease in numbers of release sites.

RHO-1 interacts with DGK-1

How does RHO-1 enhance neurotransmitter release? Mammalian RhoA has been shown to bind and inhibit the DAG kinase DGKα [Houssa et al. 1999, Los et al. 2004]. DAG kinases remove the membrane-bound second messenger DAG, which enhances neurotransmitter release in both mice and C. elegans [Lackner et al. 1999, Miller et al. 1999, Brose and Rosenmund 2002, Silinsky and Searl 2003, Brose et al. 2004], and the C. elegans ortholog of DGKα, DGK-1, acts in motor neurons to inhibit ACh release [Nurrish et al. 1999]. Interestingly, animals expressing constitutively active RHO-1(G14V) behave very similarly to both animals exposed to the DAG analog phorbol ester and animals lacking DGK-1 [Hajduron et al. 1999, Lackner et al. 1999, Miller et al. 1999, Nurrish et al. 1999], whereas animals overexpressing DGK-1 resemble animals expressing C3 transferase. Thus, DGK-1 is a possible target of negative regulation by RHO-1. To test if the interaction between RHO-1 and DGK-1 is conserved in C. elegans, we expressed HA-tagged, full-length DGK-1, together with myc-tagged, active RHO-1(G14V), in Cos7 cells. DGK-1 does coimmunoprecipitate with constitutively active RHO-1(G14V) [Fig. 2A], confirming that the interaction is conserved between mammals and nematodes. As a control, we also expressed human VSV-tagged DGKα, along with myc-tagged constitutively active RhoA(G14V), and showed that they coimmunoprecipitated [Fig. 2A].

To identify the region of DGK-1 required for coimmunoprecipitation with RHO-1, we expressed various deletions of DGK-1 [data not shown]. We found that the last 247 amino acids of DGK-1 were sufficient for binding to constitutively active RHO-1(G14V) and, at a lower level, to wild-type RHO-1 [Fig. 2B]. This DGK-1 fragment contains the DGK accessory domain, which is C-terminal to the DGK catalytic domain in all DAG kinases (Sakane and Kanoh 1997). The equivalent C-terminal fragment of human DGKα was also able to interact with constitutively active human RhoA(G14V) with a higher affinity than with wild-type RhoA, and this interaction was partially blocked by expression of C3 transferase [Fig. 2C].

In our initial studies, we discovered that RhoA constructs from three different sources contained an additional undocumented mutation [F25N]. This mutation significantly reduced the interaction between constitutively active RHO-1(G14V) and DGK-1 [Fig. 2B]. Binding of the human RhoA(G14VF25N) to DGKα was also significantly reduced by this amino acid substitution [Fig. 2C]. We tested the effect of the F25N mutation on the ability of human myc-tagged RhoA(G14V) expressed in Cos7 cells to bind other effectors. The F25N mutation did not alter the ability of constitutively active RhoA(G14V) to bind GST fusions of other Rho effectors: PKN1[1–511], mDia[47–257], and ROCKII[348–1018] [Fig. 2D]. Thus, the F25N mutation selectively reduces Rho binding to DGKα, rather than all effectors.
**Figure 2.** DGK-1 interacts with RHO-1. (A) Both full-length human DGKθ [VSV-tagged] and constitutively active RhoA(G14V) [myc-tagged] (left panels) or their C. elegans orthologs DGK-1 [HA-tagged] and RHO-1(G14V) [myc-tagged] (right panels) commounprecipitated when coexpressed in Cos7 cells. Cells were lysed and RHO-1 immunoprecipitated with the anti-myc monoclonal antibody 9E10. (Upper panel) Coimmunoprecipitated DGKθ or DGK-1 was visualized by Western blotting. Lower panels show expression controls (total lysates). The ratio of coimmunoprecipitated DGKθ [IP] to total DGKθ [VSVtotal] was determined by densitometry and is indicated below each lane. (B) Cos7 cells were cotransfected with truncated DGK-1 (HA-DGK-1acc) and wild-type, G14V, or G14VF25N RHO-1 [myc-tagged]. DGK-1 acc (lane 1) coimmunoprecipitated with RHO-1(G14V) with higher affinity than wild-type RHO-1 (lane 2), but this interaction was strongly reduced with the RHO-1(G14VF25N) mutant (lane 3). Lanes 4–6 show single-transfection controls. The ratio of coimmunoprecipitated DGK-1[IP] to total DGK-1 [VSVtotal] was determined by densitometry and is indicated below each lane. (C) Cos7 cells were cotransfected with truncated human DGKθ [VSV DGKθ acc], together with either wild-type, G14V or G14VF25N RhoA (myc-tagged), and C3 transferase. DGKθ acc coimmunoprecipitated with RhoA(G14V) [lane 1] with a higher affinity than wild-type RhoA [lane 2] or RhoA(G14VF25N) [lane 4]. Lane 3 Coexpression of C3 transferase partially decreased binding of wild-type RhoA to truncated DGKθ. Lanes 5–6 show single-transfection controls. The ratio of coimmunoprecipitated DGKθ [IP] to total DGKθ [VSVtotal] was determined by densitometry and is indicated below each lane. (D) G14V or G14VF25N RhoA (myc-tagged) were transfected into Cos7 cells. Cells were lysed, and lysates were incubated with GST fusions of PKN, mDia, or ROCKII. Following washing, bound RhoA was detected by Western blotting. The data represent the mean of three separate experiments; error bars indicate the standard error of the mean. The additional F25N mutation does not block the binding of RhoA(G14V) to PKN, mDia, or ROCKII. No significant differences were detected between G14V and G14VF25N RhoA using a two-tailed t-test [p > 0.02].

The strength of RHO-1(G14V) binding to DGK-1 correlates with the potentiation of ACh release

To assess the effect of reduced RHO-1 binding to DGK-1 on neurotransmitter release, we expressed RHO-1(G14VF25N) presynaptically using the unc-17 promoter. Presynaptic expression of the poor DGK-1-binding RHO-1(G14VF25N) caused loopy locomotion, but the rate of locomotion, while higher than in wild-type animals, was slower than in animals with neuronal expression of constitutively active RHO-1(G14V), which binds more strongly to DGK-1 [Fig. 3A]. In addition, presynaptic expression of RHO-1(G14VF25N) resulted in animals with an intermediate response to aldicarb treatment, between the response of animals expressing RHO-1(G14V), which retains full binding to DGK-1, and wild-type [Fig. 3B]. If RHO-1(G14VF25N) is defective only because of its inability to bind and inhibit DGK-1, then removal of DGK-1 should compensate for the F25N mutation. This was the case: The locomotion and aldicarb sensitivity of dgk-1-null animals expressing the RHO-1(G14VF25N) mutant that bound DGK-1 poorly was indistinguishable from animals expressing RHO-1(G14V) [Fig. 3A,B]. If RHO-1 acts through inhibition of DGK-1, then we would predict that dgk-1 mutations should not enhance the locomotion of animals expressing RHO-1(G14V). Animals expressing RHO-1(G14V) but lacking DGK-1 did not show significantly increased locomotion rates when compared with RHO-1(G14V) in a wild-type background [Fig. 3A], which suggests that RHO-1 and DGK-1 act in the same pathway.

RHO-1 also stimulates ACh release through a DGK-1-independent pathway

If RHO-1 stimulates ACh release exclusively by inhibiting DGK-1, then the removal of DGK-1, using a dgk-1-null mutant, should completely suppress the effects of lowering endogenous RHO-1 signaling. The reduced locomotion and ACh release effects of C3 transferase expressed from the unc-17 promoter were suppressed in a dgk-1-null mutant [Fig. 4A,B], but not completely. Thus, even in the complete absence of DGK-1, the inhibition of endogenous RHO-1 activity by C3 transferase is still capable of reducing locomotion and ACh release. This suggests that RHO-1 activates two presynaptic pathways, one DGK-1-dependent and one DGK-1-independent, in stimulating C. elegans locomotion.
RHO-1 increases the abundance of UNC-13 at sites of ACh release

We have previously shown that DGK-1 acts within the motor neurons to inhibit ACh release by removal of DAG (Nurrish et al. 1999). DAG increases ACh release in the motor neurons by the recruitment of the DAG-binding protein UNC-13 to neurotransmitter release sites (Lackner et al. 1999; Nurrish et al. 1999). Thus, we expected that RHO-1-mediated inactivation of DGK-1 would increase DAG levels and alter UNC-13 localization. Consistent with this, expression of constitutively activated RHO-1(G14V) from the heat-shock promoter caused an increase in the number of UNC-13S::YFP punctate structures in the dorsal nerve cord, where neuromuscular junctions are located [Fig. 5A–D,G]. To confirm that the relocation of UNC-13 was due to changes in DAG levels, we expressed a mutant form of UNC-13, H173K, which is unable to bind to DAG [Kazanietz et al. 1995; Zhang et al. 1995; Betz et al. 1998]. The non-DAG-binding UNC-13S[H173K]::GFP failed to change its localization in response to the expression of constitutively active RHO-1(G14V) [Fig. 5E,G]. Thus, RHO-1(G14V) regulates the localization of UNC-13S in the dorsal nerve cord in a DAG-dependent manner.

To confirm that the UNC-13S::YFP-containing punctate structures were sites of neurotransmitter release, we carried out double-labeling experiments, using SNB-1::CFP expressed from a motor neuron-specific promoter and UNC-13S::YFP expressed from its own pan-neural UNC-13S promoter. In the absence of RHO-1(G14V) expression, UNC-13S::YFP is diffusely localized within the motor neurons with a few discreet

Figure 3. RHO-1 enhancement of acetylcholine release is partially dependent on binding to DGK-1 and binding of UNC-13 to DAG. (A) Body bends per minute were counted for wild-type, N::RHO-1(G14V), and N::RHO-1(G14V F25N) animals in wild-type, dgk-1(sy428), and unc-13(s69);UNC13S[H173K]::GFP backgrounds. Presynaptic [unc-17 promoter] expression of the RHO-1(G14V F25N) mutant, which binds DGK-1 poorly, increases locomotion, but not as strongly as RHO-1(G14V). dgk-1(sy428) increased locomotion of animals expressing the poor DGK-1-binding RHO-1(G14V F25N) mutant but not RHO-1(G14V). The non-DAG-binding UNC-13[H173K] mutant suppresses the locomotion of RHO-1(G14V) animals to a level equivalent to that of RHO-1(G14V F25N) animals. dgk-1(sy428) animals expressing RHO-1(G14V F25N) moved slightly slower compared with RHO-1(G14V);dgk-1(sy428), although this was not significant (p > 0.02). Error bars indicate standard error of the mean. Statistical analysis was performed using a two-tailed t-test and significance is indicated using one asterisk (*) 0.001 < p < 0.02, and two asterisks (**) p < 0.001. (B) Presynaptic expression of RHO-1(G14V), and to a lesser extent the poor DGK-1-binding RHO-1(G14V F25N), cause hypersensitivity to aldicarb, suggesting that binding to DGK-1 is required for the full effect of RHO-1 on ACh release. In a dgk-1(sy428) mutant the weak DGK-1-binding RHO-1(G14V F25N) shows the same hypersensitive response to aldicarb as the RHO-1(G14V) mutant. (C,D) Replacement of endogenous UNC-13 with transgenic expression of a non-DAG-binding UNC-13S[H173K] mutant [unc-13(s69);nzIs25] partially reduced the aldicarb sensitivity resulting from the expression of RHO-1(G14V) expressed from the unc-17 promoter [neuro::RHO-1(G14V);U13[H173K]] [C], but not the aldicarb sensitivity resulting from unc-17-driven expression of the poor DGK-1-binding RHO-1(G14V F25N) mutant [neuro::RHO-1(G14V F25N);U13[H173K]] [D]. Error bars indicate standard error of the mean.

Figure 4. RHO-1 enhances acetylcholine release by DGK-1-dependent and -independent mechanisms. Presynaptic expression [from the unc-17 promoter, N::C3 transference or N::C3T] of C3 transference reduces the locomotion rate (A) and aldicarb sensitivity (B) of dgk-1(sy428) mutant animals, although not to the same level as animals with presynaptic expression of C3 transference in nonmutant animals, indicating that some but not all RHO-1 enhancement of ACh release occurs via inhibition of DGK-1. Error bars indicate standard error of the mean. Statistical analysis was performed using a two-tailed t-test, and two asterisks (**) indicates significance (p < 0.001).
puncta that are colocalized with SNB-1::CFP puncta (data not shown). Upon heat-shock-induced expression of RHO-1(G14V), the UNC-13S::YFP became more punctate and colocalized with the SNB-1::CFP puncta (Fig. 5F), although the UNC-13S::YFP appeared to spread beyond the sites defined by SNB-1::CFP. Although the number of UNC-13S::YFP puncta was increased in animals expressing RHO-1(G14V), the number of SNB-1::CFP puncta was unaffected (Supplementary Fig. 2), demonstrating that RHO-1(G14V) recruits UNC-13S to pre-existing synapses. These results indicate that RHO-1 causes a spatially restricted increase in DAG levels at sites of neurotransmitter release.

DAG-binding mutants of UNC-13 partially block the RHO-1(G14V)-induced increase in neurotransmitter release

In both C. elegans and mice hippocampal neurons, stimulation of neurotransmitter release in response to the DAG analog phorbol ester is substantially blocked by the UNC-13 [H173K] mutation, which is unable to bind DAG [Lackner et al. 1999; Rhee et al. 2002]. Expression of RHO-1(G14V) in animals possessing only the non-DAG-binding UNC-13 H173K mutant results in a partial block of RHO-1(G14V)’s effects, reducing both rates of locomotion and sensitivity to aldicarb [Fig. 3A,C]. How-
ever, the constitutively active RHO-1(G14V) retains the ability to strongly increase ACh release in UNC-13[H173K] animals, suggesting that RHO-1 stimulates release by both UNC-13-dependent and UNC-13-independent mechanisms. The UNC-13[H173K] mutant has very little effect on the aldicarb-induced paralysis of animals expressing the RHO-1(G14VF25N) mutant, which binds DGK-1 poorly [Fig. 3A,D]. These results suggest a model in which RHO-1 acts presynaptically to increase ACh release via two pathways—one depending on the inhibition of DGK-1, which causes an increase in DAG and relocation of UNC-13 to release sites, and a second that is independent of both DGK-1 and the ability of UNC-13 to bind to DAG.

Acute regulation of RHO-1 increases muscle sensitivity to acetylcholine

The heat-shock promoter we used to acutely express constitutively active RHO-1(G14V) or C3 transferase drives expression in more cell types than just neurons. Thus, we investigated whether changes in RHO-1 signaling could also affect muscle responsiveness to ACh. To do this we tested for sensitivity to levamisole, an activator of the muscle nicotinic ACh receptors. We found that heat-shock-driven expression of RHO-1(G14V) caused animals to become hypersensitive to levamisole [Fig. 6A], suggesting that RHO-1 may also increase synaptic strength at a site distinct from the motor neurons. Surprisingly, expression of C3 transferase from both the heat-shock and unc-17 promoter caused a slight increase in muscle sensitivity to levamisole [Fig. 6B,C]. Presynaptic expression of either the constitutively active RHO-1(G14V) or the poor DGK-1-binding RHO-1(G14VF25N) from the unc-17 promoter caused no change in the response to levamisole [Fig. 6C].

Discussion

We show that inhibition of endogenous RHO-1 activity with C3 transferase causes a dramatic switch in animal behavior toward slow locomotion and decreased amplitude of body bends, suggesting that signaling through RHO-1 is required for wild-type levels of locomotion. Coincident with these behavioral changes, C3 transferase decreases release of ACh when expressed either acutely in various cell types, including motor neurons and muscles [heat-shock expression in adults], or in ACh-releasing neurons (from the unc-17 promoter). Transgenic expression of a constitutively active RHO-1(G14V) mutant has the opposite effect: Animals move more quickly and with exaggerated body bends. Markers for both gross motor neuron morphology and for ACh release sites reveal no changes in response to increased RHO-1 signaling. Thus, RHO-1 acts presynaptically at pre-existing synapses to stimulate neurotransmitter release at the C. elegans neuromuscular junction and thereby modulates locomotion.

The hyperactive locomotion behavior and increased aldicarb sensitivity of RHO-1(G14V)-expressing animals is very similar to that of both wild-type animals exposed to the DAG analog phorbol ester and animals with loss-of-function mutations in goa-1 or dgk-1 [Mendel et al. 1995; Segalat et al. 1995; Hajdu-Cronin et al. 1999; Lacker et al. 1999, Miller et al. 1999; Nurrish et al. 1999]. In the case of goa-1 mutants, hyperactive locomotion is caused by an increase in both DAG and the DAG-binding UNC-13 protein at ACh release sites [Nurrish et al. 1999]. Acute expression of RHO-1(G14V) also promotes DAG-dependent accumulation of UNC-13 at sites of ACh release in dorsal motor neurons. UNC-13 is a core component of the synaptic release machinery essential for the priming of synaptic vesicle exocytosis [Richmond 1999].
et al. 1999, 2001]. Thus, we are able to show that RHO-1 signaling modulates a core component of the synaptic release machinery.

How does RHO-1(G14V) increase DAG at release sites? DGK-1 and DGK0 are DAG kinases, a family of lipid kinases that phosphorylate the membrane-bound second messenger DAG to phosphatidic acid (for reviews, see van Blitterswijk and Houssa 2000; Luo et al. 2004). As noted above, animals expressing constitutively active RHO-1(G14V) have a similar phenotype to dgk-1 mutants, and dgk-1 mutants do not increase the locomotion of animals expressing RHO-1(G14V) in the motor neurons, suggesting they act in the same pathway. Human RhoA has been shown to inhibit DGK0 in vitro, suggesting a role for RhoA in regulating DAG levels [Houssa et al. 1999], and now we show that C. elegans RHO-1 is able to bind to DGK-1. Furthermore, a RHO-1 mutant with a reduced ability to bind DGK-1, RHO-1(G14VF25N), has a reduced ability to stimulate ACh release. Our results are most consistent with a signal transduction cascade leading from activation of RHO-1, through an increase in DAG, via inhibition of DGK-1, to the recruitment of UNC-13 to sites of ACh release. We and others [Hajdu-Cronin et al. 1999; Lackner et al. 1999; Miller et al. 1999, Nurrish et al. 1999] have also shown that two antagonistic G-protein signaling pathways control DAG levels in C. elegans motor neurons. Thus, we can place this novel RHO-1 signaling pathway within a larger model of how DAG levels, and thus neurotransmitter release, are regulated within C. elegans motor neurons [Fig. 7].

In dgk-1-null mutants, UNC-13 relocates to the motor neuron plasma membrane, rather than to specific release sites [Nurrish et al. 1999]. In contrast, RHO-1[G14V] causes DAG levels to increase only at release sites, as shown by the specific localization of DAG-binding UNC-13 [although the UNC-13 does spread further than the SNB-1 release-site marker]. This localized increase in DAG suggests that activation of RHO-1 does not cause a generalized inhibition of DGK-1, but rather a specific inhibition of DGK-1 at sites of neurotransmitter release, thus ensuring that DAG levels increase only at sites of ACh release.

Two lines of evidence indicate that RHO-1 can enhance ACh release independently of DGK-1 inhibition. First, inhibition of endogenous RHO-1 by C3 transferase still reduces locomotion and ACh release in a dgk-1-null mutant, inconsistent with a model in which RHO-1 signals exclusively by inhibiting DGK-1. Second, the non-DAG-binding UNC-13[H173K] mutant only partially blocks signaling from the constitutively active RHO-1[G14V]. The UNC-13[H173K] mutant almost completely blocks the ability of low concentrations of the DAG analog PMA to stimulate release, demonstrating that UNC-13 is the primary high-affinity target of DAG effects on ACh release [Lackner et al. 1999]. These results suggest that RHO-1 can stimulate ACh release by a second, DGK-1-and DAG-independent, pathway. According to this model, we would predict that expression of RHO-1[G14V], which activates both pathways, would further increase ACh release and locomotion rates in dgk-1 mutants, which mimics activation of only one of the RHO-1 pathways. However, we did not observe any such increase; possibly the locomotion rates of dgk-1 animals may represent the maximum rate in our assay that cannot be increased, even by activation of the DGK-1-independent pathway.

Interestingly, ACh release stimulated by expression of the RHO-1[G14VF25N] mutant, which binds to DGK-1 poorly, is not inhibited by the UNC-13[H173K] mutant. Perhaps RHO-1[G14VF25N] fails to inhibit DGK-1 and stimulates ACh release entirely by the DGK-1-independent pathway. Accordingly, null mutations in dgk-1 enhance both the rate of locomotion and aldicarb sensitivity of animals expressing the poor DGK-1-binding RHO-1[G14VF25N] to equivalent levels of the strong DGK-1-binding RHO-1[G14V]. It appears that RhoA constructs containing the F25N mutation are quite common, and indeed we were unable to locate a source of RhoA without this mutation. The F25 residue is immediately N-terminal to the Rho switch 1 region and makes contacts with the Rho-binding domain in a RhoA-PKN crystal structure [Maesaki et al. 1999]. It is possible that effects of RhoA on DAG signaling have been previously missed due to the use of the RhoA[F25N] mutant.

What is the DGK-1-independent pathway by which RHO-1 stimulates release presynaptically? One possibility is that RHO-1 reorganizes presynaptic actin [Hall 1998; Dillon and Goda 2005]. Changes in the actin cyto-
skeleton are a prerequisite for exocytosis, enabling docking and fusion of secretory vesicles with the plasma membrane [for review, see Dillon and Goda 2005]. In neurons, changes in presynaptic actin modulate vesicle fusion at active zones [Morales et al. 2000], increase the movement of actin-tethered synaptic vesicles from the reserve pool to active zones [Mochida et al. 1994; Kurumi and Kidokoro 1998; Hilfiker et al. 2005], and promote endocytosis of synaptic vesicles following neurotransmitter release (Shupliakov et al. 2002). Alternatively, the DGK-1-independent RHO-1 pathway could involve the aggregation of synaptic proteins to existing synapses [Wang et al. 2005]. Constitutively active RHO-1(G14V) does not generate new aggregations of synaptobrevin [SNB-1]-labeled synaptic vesicles, ruling out the formation of new functional synapses. However, we were unable to measure numbers of SNB-1 aggregations in C3 transferase-expressing animals, so it is possible that reducing RHO-1 activity could cause the removal of release sites. A genetic screen in C. elegans for suppressors of the increased ACh release phenotype of neuronally expressed RHO-1(G14V) [E. Hiley and S.J. Nurrish, unpub.] has identified a number of recessive mutants, the characterization of these mutants should shed light on the DGK-1-independent RHO-1 signaling pathway.

A third mechanism by which RHO-1 enhances synaptic strength is revealed by the finding that expression of RHO-1(G14V) from the widely expressed heat-shock promoter causes hypersensitivity of the muscles to ACh. The simplest explanation for this finding is that the constitutively active RHO-1(G14V) acts post-synaptically to increase muscle responsiveness to ACh. Rho is known to increase the contraction by actin–myosin filaments via Rho-associated kinase, which phosphorylates myosin light chain [Kimura et al. 1996]. Alternatively, RHO-1 stimulation could increase clustering [Weston et al. 2003] or activity of the nicotinic ACh receptors by an as yet unidentified mechanism. Unexpectedly, we find that heat-shock and neuronal expression of C3 transferase also causes muscles to become slightly hypersensitive to ACh. The decreased release of ACh triggered by the C3 transferase-dependent inhibition of RHO-1 may induce homeostatic compensation in the muscles. A similar compensation effect has been observed at the Drosophila neuromuscular junction [Davis and Goodman 1998].

All of the components in our proposed DGK-1-dependent Rho signaling pathway are conserved in mammals, including RHO-1[RhoA], DGK-1[DGKδ], and UNC-13 [munc13-1]. Since RhoA, DGKδ, and munc13-1 are present in the mammalian brain, it is possible that RhoA regulates neurotransmitter release in mammals by modulating DAG levels. If so, DAG kinases and their regulators might be good targets for drugs to alter synaptic signaling in the brain.

Materials and methods

Strains

The N2 [wild-type] strain was obtained from the Caenorhabditis Genetics Center [University of Minnesota]. The dgk-1(sy428) [a gift of P. Sternberg, California Institute of Technology, Los Angeles, CA] is an early nonsense mutation that produces no detectable DGK-1 protein [Jose and Koelle 2005], and thus likely represents a null mutant. For locomotion and aldarcb assays, UNC-13 constructs were expressed in unc-13(s69) mutants. All strains were cultivated at 20°C unless otherwise stated and were maintained as described previously [Brenner 1974].

Transgenes and germline transformation

Plasmids [listed as QT#, SJN, or RJM] were constructed by standard techniques, and sequences were verified by sequencing. Transgenic strains [listed as QT] were isolated by microinjection of 100 ng/µL of plasmid, unless otherwise described below, together with ttx-3::gfp at 100 ng/µL [a gift of O. Hobert, Columbia University, New York, NY] or unc-122::gfp at 50 ng/µL [a gift of P. Sengupta, Brandeis University, Waltham, MA] as a marker. Unless otherwise stated, all injections were performed into N2 animals. Plasmids and transgenic strains were constructed as follows.

RHO-1 transgenes cDNA for RHO-1 was isolated from whole C. elegans RNA using the SMART RACE kit (Clontech) as per the manufacturer’s instructions. The sequence was modified by PCR to create the G14V mutation and subcloned either into the pPD79.48 [a gift of A. Fire, Stanford University, Stanford, CA] heat-shock vector [QT#42] or a vector driving expression from the unc-17 cholinergic-specific promoter [a 3213-base-pair [bp] fragment located -1226 to -4439 of the unc-17 start codon, a gift of J. Kaplan, Massachusetts General Hospital, Boston, MA] (QT#220). These plasmids were injected at 5 ng/µL. nzIs1 and nzIs28 contain an integrated version of the QT#42 and QT#220 plasmids, respectively. Plasmids SJN349 and SJN327 are identical to QT#42 and QT#220, respectively, except they contain a point mutation resulting in the rho-1 amino acid change F25N. Stable arrays of SJN349 [nzEx99] and SJN327 [nzEx72] were generated by injection into wild-type animals. Transgenes expressing RHO-1 N-terminally tagged with GFP, MYC, or HA lost their ability to stimulate ACh release and locomotion.

C3 transferase transgenes The C3 transferase coding sequence was a gift of R. Treisman [Cancer Research UK, London, UK]. C3 transferase was N-terminally tagged with GFP [derived from pPD05.75, a gift from A. Fire] and expressed from a heat-shock promoter [QT#99] or from the unc-17 promoter [SJN266]. These transgenes were injected at 1 ng/µL. nzEx4 and nzEx95 contain extrachromosomal versions of QT#99 and SJN266, respectively.

UNC-13 transgenes For UNC-13 and SNB-1 visualization: nuls59 contains rol-6, KP#291 [which encodes a full-length unc-13::YFP fusion gene that restores locomotion to animals carrying unc-13 alleles] and KP#282 [which encodes a SNB-1::CFP fusion expressed from the act-2 promoter [a gift of Y. Jin, University of California at Santa Cruz, Santa Cruz, CA], which is expressed in the neurons VA, DA, VB, DB, IL1, RMD, and PVQ integrated in a wild-type background. KP#273 encodes UNC-13::GFP, which contains a point mutation resulting in the amino acid change H173K. nzIs25 contains an integrated version of KP#273 in an unc-13(s69) background. Strain QT262 has both the nzIs1 [hs::rho-1[G14V]] and nuls59 integrants. Strain QT426 has both the nuls59 and nzIs28[N::rho-1[G14V]] integrants. Strain QT336 has the nzIs1 and nzIs25 integrated arrays in the unc-13(s69) background. As rol-6 expression interferes with locomotion and aldarcb assays, we used nuls46, which is an integration of the KP#268 [UNC-13::GFP] plasmid instead.
of *nuIs59*. Strain QT148 has both the *n2Is1* and *nuIs46* integrants in the *unc-13*(s69) background. Strain QT328 has the *n2Is25* and *n2Is28* integrated arrays in an *unc-13*(s69) background. *n2Ex122* has SJN327 [p.unc-17::RHO-1(G14VF25N)], KP#291, and KP#282 as a stable array in *unc-13*(s69) animals.

**Induction of heat-shock-inducible transgenes**

In all cases, expression from the heat-shock promoter was achieved using two rounds of heat shock for 60 min at 30°C, separated by 30 min at 20°C, followed by recovery for 30 min at 20°C.

**Microscopy**

Strains expressing *punc-47::GFP*, *punc-13:UNC13S::YFP*, *pacr-2::SNB-1::CFP*, or *punc-13:UNC13S[H173K][H173R]::GFP* were imaged by mounting on agarose pads and viewed on a Bio-Rad 2100 upright multiphoton confocal microscope with a Nikon 60× objective. Images were obtained using LaserSharp software (Bio-Rad). Digital images were processed to give maximum intensity projections of a z-series using ImageJ (NIH). Images were blinded with respect to genotype and treatment, and *UNC-13S::YFP* and SNB-1::CFP puncta were counted manually. The following strains were used for microscopy: EG1285 [oxIs12], QT195 [n2Is1;oxIs12], QT316 [n2Is28;oxIs12], QT427 [n2Ex95;oxIs12], KP1683 [nuIs59], QT262 [n2Is1;nuIs59], QT181 [n2Is25], QT336 [n2Is1;nuIs25], QT426 [n2Is28;nuIs59].

**Analysis of locomotion and sensitivity to drug treatment**

Sensitivity to 1 mM aldicarb (Greyhound Chromatography) or 100 μM levamisole (Sigma) on NGM plates with food was determined by analyzing the onset of paralysis as described previously [Nurrish et al. 1999]. For each experiment, 25 animals were tested, and each experiment was repeated at least five times. For locomotion rates, the number of body bends per minute was counted by visual inspection, and animals were assayed on NGM plates in the presence of food. Each animal was assayed three times for 1 min each. At least five animals were tested in all cases.

**Plasmids for mammalian expression and recombinant protein purification**

pcDNA1DGK9V5SV was kindly provided by W.J. van Blitterswijk [Nederlands Kanker Instituut, Amsterdam, Netherlands]. pcDNA3.1DGK-accVSV containing residues 731–1018) for purification of recombinant –cells and pGexKG-PKN(1–257), and GSTROCKII(348–1018) were performed as described (Sahai et al. 1998) with the following modifications. pcDNA3.1mycV14RhoA and pcDNA3.1mycV14N25RhoA were transfected into Cos7 cells as described above. Forty-eight hours after transfection, cells were lysed in 150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 5 mM MgCl2, 1% Nonidet P-40, and protease inhibitors. Immunoprecipitated proteins were subjected to SDS–polyacrylamide gel electrophoresis and immunoblotting, together with 20 μg of total lysates, using standard methods. The following antibodies were used for immunoprecipitation and immunoblotting: anti-myc tag 9E10 (Santa Cruz), anti-VSV tag (Abcam), anti-β-tubulin E7 (Developmental Studies Hybridoma Bank, University of Iowa), and anti-HA [Santa Cruz]. Densitometric analysis was performed using Quantity One software (Bio-Rad). We attempted to measure the DAG kinase activity of DGK-1 bound to RHO-1; however, levels of coimmunoprecipitated DGK-1 were too low for results from the DAG kinase assay [Nurrish et al. 1999; Jose and Koelle 2005] to be reliable.

**GST pulldowns**

GST pulldowns using recombinant GST-PKN(1–511), GST-mDia(47–257), and GSTROCKII(348–1018) were performed as described (Sahai et al. 1998) with the following modifications. pcDNA3.1mycV14RhoA and pcDNA3.1mycV14N25RhoA were transfected into Cos7 cells as described above. Forty-eight hours after transfection, cells were lysed in 150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 5 mM MgCl2, 1% Nonidet P-40, and protease inhibitors. Two-hundred micrograms of cell lysate was incubated with 20 μg of GST fusion protein for 2 h at 4°C, and washes were performed. Following SDS–polyacrylamide gel electrophoresis and immunoblotting, bands were detected using a FluorSmax fluorimeter, and densitometric analysis was carried out using Quantity One software (Bio-Rad). Values represent the means of three separate experiments.

**Statistical analysis**

In all cases statistical analysis was performed using an unpaired t-test. *P* values between 0.02 and 0.001 (significant) are indicated on figures using one asterisk, and *P* values of 0.001 or less (highly significant) are indicated with two asterisks.

**Acknowledgments**

We thank the following individuals for strains, plasmids, and advice: A. Hall, J. Kaplan, R. Treisman, W.J. van Blitterswijk, P. Sengupta, P. Sternberg, Y. Jin, A. Fire, J. Pitcher, and the Caenorhabditis Genetics Center. We thank A. Hall, M. Ralf, Y. Goda, and M. Laycock for comments on the manuscript. E.H. is funded by a 4-year MRC Ph.D. studentship.


Rho is a presynaptic activator of neurotransmitter release at pre-existing synapses in *C. elegans*

Rachel McMullan, Emma Hiley, Paul Morrison, et al.

*Genes Dev.* 2006 20: 65-76
Access the most recent version at doi:10.1101/gad.359706

**Supplemental Material**

http://genesdev.cshlp.org/content/suppl/2005/12/30/20.1.65.DC1.html

**References**

This article cites 61 articles, 27 of which can be accessed free at: http://genesdev.cshlp.org/content/20/1/65.full.html#ref-list-1

**Email Alerting Service**

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.